Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

“…126 The adverse events more commonly seen with axitinib (≥10% difference) than with sorafenib treatment were diarrhea, hypertension, weight loss, decreased appetite, dysphonia, hypothyroidism, and upper abdominal pain; adverse events more commonly seen with sorafenib treatment included palmar-plantar erythrodysesthesia, rash, alopecia, and erythema. 126 The difference in PFS between patients treated with axitinib versus sorafenib is not statistically significant; however, the results demonstrated clinical activity of axitinib with acceptable toxicity profile in the first-line setting.…”

“…To determine whether this holds true in the first-line setting, a randomized, open-label, phase III trial was conducted in newly diagnosed patients randomized (2:1) to receive axitinib (5 mg twice daily) or sorafenib (400 mg twice daily). 126 The median PFS seen in patients treated with axitinib was 10.1 months (95% CI, 7.2-12.1) and for those treated with sorafenib was 6.5 months (95% CI, 4.7-8.3). 126 The adverse events more commonly seen with axitinib (≥10% difference) than with sorafenib treatment were diarrhea, hypertension, weight loss, decreased appetite, dysphonia, hypothyroidism, and upper abdominal pain; adverse events more commonly seen with sorafenib treatment included palmar-plantar erythrodysesthesia, rash, alopecia, and erythema.…”

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin

“…Accordingly, it was postulated that the universal, early loss of VHL would render ccRCC susceptible to the inhibition of the VEGF signaling pathway (39). Indeed, the mainstream treatment for metastatic ccRCC encompasses antibody against VEGF or inhibitors of VEGFR, such as bevacizumab (40,41), sorafenib (42,43), sunitinib (44,45), pazopanib (46,47), and axitinib (48,49). However, the complete functional loss of VHL alone was Genomic studies have linked mTORC1 pathway-activating mutations with exceptional response to treatment with allosteric inhibitors of mTORC1 called rapalogs.…”

Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

“…Serious treatment-related adverse events included atrial flutter, cardiac arrest, MI, asthenia, aorto-duodenal fistula and hypertensive crisis < 1% each (1 patient). Besides, 1 patient in the axitinib group died of treatment-related cardiac arrest [65].…”